Ellipsys系统经皮动静脉瘘创建的中期结果、技术建议与维护算法
单中心回顾性研究纳入234例透析前或终末期肾病患者,使用Ellipsys设备创建经皮动静脉瘘(pAVF),技术成功率99%,1年一期、一期辅助和二期通畅率分别为54%、85%和96%,无显著不良事件,认为pAVF快速安全,可作为不适合远端桡动脉-头静脉瘘患者的次选。
要点
- Ellipsys pAVF技术成功率高(99%),手术时间短(平均15分钟)。
- 1年一期通畅率54%,一期辅助通畅率85%,二期通畅率96%。
- 仅1%需转为手术瘘,10%因穿刺困难需浅表化,成熟时间平均4周。
核心结论
- Ellipsys pAVF设备可快速、安全地建立可靠的自体血管通路,技术成功、通畅率和成熟率优良。
- 对于不适合远端桡动脉-头静脉动静脉瘘的患者,pAVF应考虑为下一个优先选择的通路方式。
研究设计与样本
- 单中心回顾性研究,纳入2017年5月至2019年7月连续234例透析前或终末期肾病患者,均使用Ellipsys设备创建pAVF。
- 平均年龄64岁,男性148例(63%),平均随访252天(范围83-696天)。
主要发现
- 技术成功232例(99%),平均手术时间15分钟(范围7-35分钟)。
- 1年一期、一期辅助和二期通畅率分别为54%、85%和96%。
- 平均pAVF流量923 mL/min(范围425-1440 mL/min)。
- 无显著不良事件;仅3例(1%)后期需将pAVF吻合转为手术瘘。
临床怎么用
- Ellipsys pAVF可作为不适合远端桡动脉-头静脉瘘患者的次选血管通路选择。
- 术后需关注深部流出静脉穿刺困难,必要时行浅表化手术。
局限性
- 单中心回顾性研究设计。
- 随访时间有限(平均252天),中期结果需更长期验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to report our midterm results of percutaneous arteriovenous fistula (pAVF) creation using the Ellipsys (Avenu Medical, San Juan Capistrano, Calif) device and to present technical recommendations and our algorithm of pAVF maintenance. METHODS: A single-center comprehensive database of all consecutive predialysis and end-stage renal disease patients who had a pAVF creation with the Ellipsys device was reviewed retrospectively. Study end points included technical success, maturation, functional patency, and required interventions. RESULTS: Between May 2017 and July 2019, there were 234 patients (mean age, 64 years; 148 male [63%]) who had a pAVF created. Technical success was achieved in 232 individuals (99%), and average duration of the procedure was 15 minutes (7-35 minutes). Average follow-up was 252 days (range, 83-696 days). The 1-year primary, primary assisted, and secondary patency rates were 54%, 85%, and 96%, respectively. Average pAVF flow was 923 mL/min (range, 425-1440 mL/min). There were no significant adverse events related to the procedure. Only three patients (1%) required a later conversion of the pAVF anastomosis to a surgical fistula. Twenty-four (10%) patients required superficialization of deep outflow veins because of difficult cannulation. Average maturation time was 4 weeks (range, 1-12 weeks). Fourteen patients (6%) had early (<2 weeks after creation) cannulation of the pAVF. CONCLUSIONS: The Ellipsys pAVF device allows the rapid and safe creation of a reliable autogenous access. Rates of technical success, patency, and maturation were excellent. For patients unsuited for a distal radiocephalic arteriovenous fistula, it should be considered the next preferred access option.
引用
- Mallios A, Bourquelot P, Franco G, et al. Midterm results of percutaneous arteriovenous fistula creation with the Ellipsys Vascular Access System, technical recommendations, and an algorithm for maintenance. J Vasc Surg. 2020. PMID: 32276012. doi:10.1016/j.jvs.2020.02.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。